Role of human milk oligosaccharides in Group B Streptococcus colonisation
- PMID: 27588204
- PMCID: PMC5007626
- DOI: 10.1038/cti.2016.43
Role of human milk oligosaccharides in Group B Streptococcus colonisation
Abstract
Group B Streptococcus (GBS) infection is a major cause of morbidity and mortality in infants. The major risk factor for GBS disease is maternal and subsequent infant colonisation. It is unknown whether human milk oligosaccharides (HMOs) protect against GBS colonisation. HMO production is genetically determined and linked to the Lewis antigen system. We aimed to investigate the association between HMOs and infant GBS colonisation between birth and postnatal day 90. Rectovaginal swabs were collected at delivery, as well as colostrum/breast milk, infant nasopharyngeal and rectal swabs at birth, 6 days and days 60-89 postpartum from 183 Gambian mother/infant pairs. GBS colonisation and serotypes were determined using culture and PCR. (1)H nuclear magnetic resonance spectroscopy was used to characterise the mother's Lewis status and HMO profile in breast milk. Mothers who were Lewis-positive were significantly less likely to be colonised by GBS (X (2)=12.50, P<0.001). Infants of Lewis-positive mothers were less likely GBS colonised at birth (X (2)=4.88 P=0.03) and more likely to clear colonisation between birth and days 60-89 than infants born to Lewis-negative women (P=0.05). There was no association between Secretor status and GBS colonisation. In vitro work revealed that lacto-N-difucohexaose I (LNDFHI) correlated with a reduction in the growth of GBS. Our results suggest that HMO such as LNDFHI may be a useful adjunct in reducing maternal and infant colonisation and hence invasive GBS disease. Secretor status offers utility as a stratification variable in GBS clinical trials.
Conflict of interest statement
NJA has received support from Medela to attend an educational conference but declared no other conflict of interest. MJH has received support from Danone International to attend an educational conference but declared no other conflict of interest. In the past five years, NM has received consultancy fees from Ferring Pharmaceuticals, speaker honorarium for an educational meeting funded by Nestle International in which they had no organisational involvement and grants from the Medical Research Council, National Institute of Heath Research, Westminster Children's Trust Fund, Child Growth Foundation, Action Medical Research, HCA International, Bliss, British Heart Foundation and Department of Health. BK is funded by the Medical research Council to conduct research into vaccines and immunity. The other authors declare no conflict of interest.
Figures



References
-
- Vergnano S, Menson E, Kennea N, Embleton N, Russell AB, Watts T et al. Neonatal infections in England: the NeonIN surveillance network. Arch Dis Child Fetal Neonatal Ed 2011; 96: F9–F14. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources